GSK256066 Clinical Trials

Size	Price	Qty
10mg	USD 370

Clinical Trials

GlaxoSmithKline has sponsored multiple clinical trials evaluating GSK256066 for the treatment of inflammatory respiratory disorders, specifically seasonal allergic rhinitis, asthma, and chronic obstructive pulmonary disease. These completed, industry-led Phase I and Phase II studies focused on assessing the drug's safety, tolerability, and therapeutic efficacy.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00549679	COMPLETED	Pulmonary Disease, Chronic Obstructive	GlaxoSmithKline	2007-10-04	PHASE2
NCT00549744	COMPLETED	Asthma	GlaxoSmithKline	2007-11-16	PHASE2
NCT00612118	COMPLETED	Allergic Rhinitis; Rhinitis, Allergic, Seasonal	GlaxoSmithKline	2008-02	PHASE2
NCT00612820	COMPLETED	Rhinitis, Allergic, Seasonal	GlaxoSmithKline	2008-01	PHASE2
NCT00515268	COMPLETED	Pulmonary Disease, Chronic Obstructive	GlaxoSmithKline	2007-09-27	PHASE1
NCT00612118	Completed	Allergic Rhinitis\|Rhinitis Allergic Seasonal	GlaxoSmithKline	2008-02	Phase 2
NCT00612820	Completed	Rhinitis Allergic Seasonal	GlaxoSmithKline	2008-01	Phase 2
NCT00549744	Completed	Asthma	GlaxoSmithKline	2007-11-16	Phase 2
NCT00549679	Completed	Pulmonary Disease Chronic Obstructive	GlaxoSmithKline	2007-10-04	Phase 2
NCT00515268	Completed	Pulmonary Disease Chronic Obstructive	GlaxoSmithKline	2007-09-27	Phase 1
NCT00464568	COMPLETED	Rhinitis, Allergic, Seasonal	GlaxoSmithKline	2007-03-28	PHASE2
NCT00464568	Completed	Rhinitis Allergic Seasonal	GlaxoSmithKline	2007-03-28	Phase 2
NCT00377728	COMPLETED	Rhinitis, Allergic, Seasonal; Seasonal Allergic Rhinitis	GlaxoSmithKline	2006-03	PHASE2
NCT00430157	COMPLETED	Rhinitis, Allergic, Seasonal; Seasonal Allergic Rhinitis	GlaxoSmithKline	2007-01	PHASE2
NCT00380354	COMPLETED	Asthma; Mild Asthma	GlaxoSmithKline	2006-09	PHASE2
NCT00445510	COMPLETED	Asthma	GlaxoSmithKline	2006-06	PHASE2

(data from https://clinicaltrials.gov, updated on 2017-07-28)

Check the GSK256066 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

GSK256066 is an exceptionally potent and selective phosphodiesterase 4 inhibitor that binds PDE4B with picomolar affinity to block cyclic AMP degradation, thereby elevating intracellular cAMP levels and suppressing lipopolysaccharide-induced tumor necrosis factor production. This cellular inhibition reduces inflammatory leukocyte infiltration and pulmonary airway inflammation, providing therapeutic utility in clinical trial conditions such as asthma, allergic rhinitis, and chronic obstructive pulmonary disease.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).